ATE198743T1 - Imidazolidin-derivate und ihre verwendung - Google Patents
Imidazolidin-derivate und ihre verwendungInfo
- Publication number
- ATE198743T1 ATE198743T1 AT95926500T AT95926500T ATE198743T1 AT E198743 T1 ATE198743 T1 AT E198743T1 AT 95926500 T AT95926500 T AT 95926500T AT 95926500 T AT95926500 T AT 95926500T AT E198743 T1 ATE198743 T1 AT E198743T1
- Authority
- AT
- Austria
- Prior art keywords
- groups
- group
- alkyl
- esterified
- active ingredient
- Prior art date
Links
- 150000002461 imidazolidines Chemical class 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 102000005862 Angiotensin II Human genes 0.000 abstract 1
- 101800000733 Angiotensin-2 Proteins 0.000 abstract 1
- 229940119334 Chymase inhibitor Drugs 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical class C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000001133 acceleration Effects 0.000 abstract 1
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 229950006323 angiotensin ii Drugs 0.000 abstract 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 239000003601 chymase inhibitor Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20786794 | 1994-07-29 | ||
| JP33370694 | 1994-12-07 | ||
| PCT/JP1995/001485 WO1996004248A1 (en) | 1994-07-29 | 1995-07-26 | Imidazolidine derivative and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE198743T1 true ATE198743T1 (de) | 2001-02-15 |
Family
ID=26516513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95926500T ATE198743T1 (de) | 1994-07-29 | 1995-07-26 | Imidazolidin-derivate und ihre verwendung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5691335A (de) |
| EP (1) | EP0721944B1 (de) |
| AT (1) | ATE198743T1 (de) |
| AU (1) | AU3086095A (de) |
| DE (1) | DE69519921T2 (de) |
| ES (1) | ES2155134T3 (de) |
| WO (1) | WO1996004248A1 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5912261A (en) * | 1994-12-20 | 1999-06-15 | Nippon Zoki Pharmaceutical Co., Ltd. | Carboxyalkyl heterocyclic derivatives |
| US6197806B1 (en) | 1995-12-20 | 2001-03-06 | Nippon Zoki Pharmaceutical Co., Ltd. | Eliminating agent for activated oxygen and free radicals |
| JPH10182460A (ja) * | 1996-12-27 | 1998-07-07 | Nippon Zoki Pharmaceut Co Ltd | ３−デオキシグルコソン生成阻害剤 |
| US20050267148A1 (en) * | 1998-07-15 | 2005-12-01 | Teijin Limited | Benzimidazole derivative |
| CN1187337C (zh) | 1998-07-15 | 2005-02-02 | 帝人株式会社 | 硫代苯并咪唑衍生物 |
| KR100381214B1 (ko) * | 1998-08-10 | 2003-09-22 | 주식회사 엘지생명과학 | 항암제로유용한이미다졸리딘-2,4-디온유도체및그의제조방법 |
| EP1112749A4 (de) * | 1998-08-20 | 2004-06-16 | Senju Pharma Co | Vorbeugende mittel oder heilmittel gegen störungen des augenkreislaufs |
| ATE326451T1 (de) * | 1998-08-21 | 2006-06-15 | Daiichi Asubio Pharma Co Ltd | Chinazolin derivate und therapeutische verwendungen davon |
| AU754989B2 (en) | 1998-11-16 | 2002-11-28 | Nippon Zoki Pharmaceutical Co., Ltd. | A therapeutic agent for intractable vasculitis |
| EP1136488A4 (de) * | 1998-12-01 | 2002-06-12 | Meiji Seika Kaisha | Sf2809-i, ii, iii. vi, v und vi-verbindungen mit chymase-inhibierender wirkung |
| WO2001030388A1 (en) * | 1999-10-25 | 2001-05-03 | Senju Pharmaceutical Co., Ltd. | Tension-relieving agents for ciliary muscle |
| EP1142586B1 (de) | 1999-11-01 | 2007-04-25 | Daiichi Asubio Pharma Co., Ltd. | Verwendung von chymase hemmern gegen vaskuläre lipidablagerung |
| US6300503B1 (en) * | 1999-12-17 | 2001-10-09 | Dixie Chemical Company | Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same |
| KR20010108519A (ko) | 2000-02-22 | 2001-12-07 | 도리이 신이치로 | 키마제 억제제를 유효성분으로 하는 선유증의 예방 또는치료약 |
| DE60121695T2 (de) * | 2000-02-22 | 2007-08-30 | Daiichi Asubio Pharma Co., Ltd. | Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen |
| AU3413501A (en) | 2000-02-22 | 2001-09-03 | Daiichi Asubio Pharma Co., Ltd. | Preventive or therapeutic drugs for various eosinophilia-related diseases containing chymase inhibitors as the active ingredient |
| JP4711523B2 (ja) | 2001-02-13 | 2011-06-29 | 日本臓器製薬株式会社 | 低アルブミン血症改善剤 |
| JPWO2002083649A1 (ja) * | 2001-04-11 | 2004-08-05 | 千寿製薬株式会社 | 新規イミダゾリジンジオン誘導体およびその医薬用途 |
| MXPA05000536A (es) * | 2002-07-30 | 2005-04-19 | Sod Conseils Rech Applic | Uso de los inhibidores de la quimasa para la prevencion y/o tratamiento de la falla de injertos arterio-venosos. |
| FR2845383B1 (fr) * | 2002-10-04 | 2004-12-31 | Fournier Lab Sa | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique |
| WO2004031160A2 (fr) * | 2002-10-04 | 2004-04-15 | Laboratoires Fournier S.A. | Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete |
| FR2845384B1 (fr) * | 2002-10-04 | 2004-12-31 | Fournier Lab Sa | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique |
| ES2636943T3 (es) | 2003-05-09 | 2017-10-10 | Toray Industries, Inc. | Beraprost y un inhibidor del sistema renina-angiotensina para usar en el tratamiento de enfermedades renales |
| US7423155B2 (en) | 2003-11-14 | 2008-09-09 | 3M Innovative Properties Company | N-sulfonyldicarboximide containing tethering compounds |
| US7361767B2 (en) * | 2003-11-14 | 2008-04-22 | 3M Innovative Properties Company | N-sulfonyldicarboximide containing tethering compounds |
| EP2299266A1 (de) | 2003-12-19 | 2011-03-23 | The Regents of the University of California | Verfahren und Materialien zur Beurteilung von Prostatakrebstherapien |
| NZ550102A (en) | 2004-02-24 | 2010-10-29 | Univ California | Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives) |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| US7544756B2 (en) | 2005-09-30 | 2009-06-09 | 3M Innovative Properties Company | Crosslinked polymers with amine binding groups |
| BRPI0709771B1 (pt) | 2006-03-27 | 2022-01-25 | The Regents Of The University Of California | Composto e composição farmacêutica |
| NZ596260A (en) | 2006-03-29 | 2013-05-31 | Univ California | Diarylthiohydantoin compounds |
| TWI469971B (zh) | 2007-10-26 | 2015-01-21 | Univ California | 二芳基乙內醯脲類化合物 |
| WO2010088195A1 (en) | 2009-01-30 | 2010-08-05 | Boehringer Ingelheim International Gmbh | Azaquinazolinediones useful as chymase inhibitors |
| EP3124481B1 (de) | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgenrezeptormodulatoren und verwendungen davon |
| WO2014052237A1 (en) | 2012-09-26 | 2014-04-03 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| EP2945628B1 (de) | 2013-01-15 | 2020-04-15 | Aragon Pharmaceuticals, Inc. | Androgenrezeptormodulator in kombination mit abirateronacetat und prednison zur behandlung von prostatkrebs |
| CA2929763A1 (en) * | 2013-11-08 | 2015-05-14 | Bayer Pharma Aktiengesellschaft | Substituted uracils as chymase inhibitors |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| KR102521955B1 (ko) * | 2016-06-14 | 2023-04-13 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온 |
| WO2017218633A1 (en) * | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists |
| WO2019023448A1 (en) * | 2017-07-26 | 2019-01-31 | Emory University | INHIBITORS OF NADPH OXIDASE AND THEIR USE |
| KR20240096623A (ko) | 2017-10-16 | 2024-06-26 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1207391B (de) * | 1962-05-30 | 1965-12-23 | Degussa | Verfahren zur Herstellung von 3-Benzoyl-5, 5-dimethylhydantoinen |
| US4166124A (en) * | 1970-05-15 | 1979-08-28 | U.S. Philips Corporation | Insecticidal 2,6-dihalobenzoyl urea derivatives |
| JPS5371073A (en) * | 1976-12-03 | 1978-06-24 | Sumitomo Chem Co Ltd | 1-cyclic alkyl carbonyl-3(3,5-dihalogenophenyl)hydantoin derivs., process fo r their preparation and fungicides for agriculture and horti culture contg. the same as active constituents |
| JPS5855468A (ja) * | 1981-09-25 | 1983-04-01 | Sumitomo Chem Co Ltd | ５−クロロヒダントイン誘導体、その製造法およびそれを有効成分として含有する殺虫剤 |
| US4474796A (en) * | 1983-02-04 | 1984-10-02 | Sumitomo Chemical Company, Limited | Insecticidal substituted hydantoins |
| JPH068281B2 (ja) * | 1985-09-19 | 1994-02-02 | 持田製薬株式会社 | ヒダントイン誘導体及びそれを有効成分とするアルド−スレダクタ−ゼ阻害剤 |
-
1995
- 1995-07-26 ES ES95926500T patent/ES2155134T3/es not_active Expired - Lifetime
- 1995-07-26 DE DE69519921T patent/DE69519921T2/de not_active Expired - Fee Related
- 1995-07-26 AU AU30860/95A patent/AU3086095A/en not_active Abandoned
- 1995-07-26 EP EP95926500A patent/EP0721944B1/de not_active Expired - Lifetime
- 1995-07-26 US US08/615,277 patent/US5691335A/en not_active Expired - Fee Related
- 1995-07-26 AT AT95926500T patent/ATE198743T1/de not_active IP Right Cessation
- 1995-07-26 WO PCT/JP1995/001485 patent/WO1996004248A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69519921T2 (de) | 2001-06-13 |
| DE69519921D1 (de) | 2001-02-22 |
| US5691335A (en) | 1997-11-25 |
| EP0721944B1 (de) | 2001-01-17 |
| ES2155134T3 (es) | 2001-05-01 |
| EP0721944A4 (de) | 1997-01-02 |
| AU3086095A (en) | 1996-03-04 |
| EP0721944A1 (de) | 1996-07-17 |
| WO1996004248A1 (en) | 1996-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69519921D1 (de) | Imidazolidin-derivate und ihre verwendung | |
| ATE225770T1 (de) | Difluoroprostaglandin-derivate und ihre anwendung | |
| EP1070710A3 (de) | Dithiolan Derivate, deren Herstellung und deren therapeutischer Wirkung | |
| IL184539A (en) | The heteroaryl sulfonamide compounds, their preparations and their uses | |
| DE69738245D1 (de) | 1,2-Diphenylpyrrol-Derivate, ihre Herstellung und therapeutische Verwendung | |
| AU624526B2 (en) | Benzopyran compounds, processes for their production and pharmaceutical compositions | |
| DE69532216D1 (de) | 1-Acetyl-5-Bromo-4,6-Dimethylindolin | |
| AU7517400A (en) | N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent | |
| FR2800735B1 (fr) | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation | |
| EP0549796A4 (en) | Diphenylpiperazine derivative and drug for circulatory organ containing the same | |
| DE69623497D1 (de) | 1-methylcarbapenem-derivate | |
| DE60016384D1 (de) | Chondrogonese promotoren und indolin-2-on derivate | |
| ATE284684T1 (de) | Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut | |
| HUP9700810A2 (hu) | Diozmetinsavak és -észterek, és a vegyületeket tartalmazó gyógyszerkészítmények | |
| BRPI0408675A (pt) | derivados de talidomida solúveis em água | |
| ATE360423T1 (de) | Verwendung von chymase hemmern gegen vaskuläre lipidablagerung | |
| KR950702544A (ko) | 비페닐메탄 유도체 및 이를 함유하는 약제 | |
| ATE123487T1 (de) | Derivate der kaffeinsäure und sie enthaltende pharmazeutische zusammensetzungen. | |
| DE69713648D1 (de) | Benzopyranderivate und ihre Verwendung zur Behandlung von Herzkrankheiten | |
| IT1276161B1 (it) | Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi | |
| DE3782235D1 (de) | Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz. | |
| DE3782229D1 (de) | Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |